Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large differences in
the pharmacokinetics of a number of clinically important drugs. On the basis of their ability to …

Clinical implementation of pharmacogenomics (PGx) leads to personalized medicine, which
improves the efficacy, safety, and cost-effectiveness of treatments. Although PGx-based …

Majority of cancer cells upregulate co-inhibitory molecule B7-H1 which confers resistance to
anti-tumor immunity, allowing cancers to escape from host immune surveillance. We …

Warfarin-dosing algorithms incorporating CYP2C9 and VKORC1 −1639G>A improve dose
prediction compared with algorithms based solely on clinical and demographic factors. …

Background and objective Rifampin (INN, rifampicin) causes several drug interactions with
coadministered antidiabetic drugs. Rosiglitazone is a novel thiazolidinedione antidiabetic …

The early detection of potential drug‐drug interactions is an important issue of drug discovery
that has led to the development of high‐throughput screening (HTS) methods for potential …

The ability of antipsychotic drugs to inhibit the catalytic activity of five cytochrome P-450 (CYP)
isoforms was compared using in vitro human liver microsomal preparations to evaluate …

Aims To determine the frequencies of CYP2C9 variants in the Korean population and compare
them with the frequencies in other ethnic populations. Methods Genotyping of CYP2C9*2 …

Objective This study was addressed to understand the underlying mechanism of the
substrate-dependent effect of genetic variation in SLCO1B1, which encodes OATP1B1 (organic …

A simple and accurate liquid chromatography (LC)–tandem mass spectrometry (MS/MS)
method for the quantitation of 20 anti-tuberculosis (anti-TB) drugs in human plasma, was …